A Seamless Phase 2a/2b, Randomized, Double-Blind, Placebo- and Active-Controlled, Multiple-Arm, Multiple-Stage, Adaptive Study Evaluating the Efficacy and Safety of LAD191 in Adults With Moderate-to-Severe Hidradenitis Suppurativa

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521293-34-00

Acronym

M-27134-10

Enrollment

128

Registered

2025-11-03

Start date

2025-12-09

Completion date

Unknown

Last updated

2026-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate-to-severe hidradenitis suppurativa

Brief summary

Proportion of participants achieving HiSCR 50, Safety endpoint: Frequency and severity of treatment-emergent AEs, SAEs, AEs leading to discontinuation, and AESIs, Safety endpoint: Local tolerance, vital signs, ECGs, and clinical laboratory parameters

Interventions

DRUGADALIMUMAB

DRUGLAD191 placebo

DRUGLAD191

DRUGSODIUM CHLORIDE

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Proportion of participants achieving HiSCR 50, Safety endpoint: Frequency and severity of treatment-emergent AEs, SAEs, AEs leading to discontinuation, and AESIs, Safety endpoint: Local tolerance, vital signs, ECGs, and clinical laboratory parameters	—

Countries

France, Germany, Ireland, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026